FDA Approves Zanubrutinib for Relapsed or Refractory Follicular Lymphoma

$FDA Approves Zanubrutinib for Relapsed or Refractory Follicular Lymphoma$

On March 7, the US Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib in combination with obinutuzumab for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

For more information read the FDA announcement and BeiGene announcement.

Posted 3/11/2024